ZNF746 (Zinc Finger Protein 746), also known as Parkin-Interacting Protein (PRIP) or Parkinson's Disease Protein 6 (PDRP6), is a transcription factor that functions as a transcriptional repressor, primarily targeting genes involved in mitochondrial biogenesis and oxidative stress response. Originally identified as a risk gene for Parkinson's disease through genome-wide association studies (GWAS)[@gwas], ZNF746 has emerged as a critical regulator of mitochondrial homeostasis in dopaminergic neurons. The gene encodes a protein containing a KRAB (Kruppel-associated box) transcriptional repression domain and multiple C2H2-type zinc finger motifs, enabling it to bind DNA and modulate gene expression programs critical for neuronal survival["@znfa"][@role].
ZNF746 (Zinc Finger Protein 746), also known as Parkin-Interacting Protein (PRIP) or Parkinson's Disease Protein 6 (PDRP6), is a transcription factor that functions as a transcriptional repressor, primarily targeting genes involved in mitochondrial biogenesis and oxidative stress response. Originally identified as a risk gene for Parkinson's disease through genome-wide association studies (GWAS)[@gwas], ZNF746 has emerged as a critical regulator of mitochondrial homeostasis in dopaminergic neurons. The gene encodes a protein containing a KRAB (Kruppel-associated box) transcriptional repression domain and multiple C2H2-type zinc finger motifs, enabling it to bind DNA and modulate gene expression programs critical for neuronal survival["@znfa"][@role].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ZNF746 - Zinc Finger Protein 746</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ZNF746</td></tr>
<tr><td><strong>Full Name</strong></td><td>Zinc Finger Protein 746</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>7q36.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[155054](https://www.ncbi.nlm.nih.gov/gene/155054)</td></tr>
<tr><td><strong>OMIM</strong></td><td>614629</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164684</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8N2U4](https://www.uniprot.org/uniprot/Q8N2U4)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, ALS, Alzheimer's Disease</td></tr>
</table>
</div>
The ZNF746 gene spans approximately 22 kb on the long arm of chromosome 7 at position 7q36.1, a genomic region that has been implicated in Parkinson's disease susceptibility through multiple GWAS analyses[@gwas]. The gene consists of 5 exons encoding a protein of 724 amino acids with a molecular weight of approximately 80 kDa. The genomic architecture includes a 5' promoter region containing putative Sp1 and AP-1 transcription factor binding sites, suggesting regulation by cellular stress signals.
The ZNF746 protein contains several distinct functional domains:
ZNF746's primary function is the transcriptional repression of genes involved in mitochondrial biogenesis, particularly those regulated by PGC-1α (PPARGC1A)[@znfa]. PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis, coordinating the expression of nuclear-encoded mitochondrial proteins through activation of transcription factors including NRF-1, NRF-2, and TFAM.
ZNF746 represses PGC-1α expression through direct binding to the PPARGC1A promoter, recruiting histone deacetylases and establishing repressive chromatin marks. Under normal physiological conditions, this repression serves as a regulatory check to prevent excessive mitochondrial proliferation. However, dysregulated ZNF746 activity contributes to mitochondrial dysfunction in Parkinson's disease[@pw1].
Beyond PGC-1α regulation, ZNF746 modulates expression of multiple genes involved in the oxidative stress response:
ZNF746 physically interacts with the [PINK1](/genes/pink1)-[Parkin](/genes/parkin) mitophagy pathway, a critical quality control mechanism for mitochondrial integrity[@pw2]. Under normal conditions, ZNF746 is ubiquitinated by Parkin and targeted for degradation. In PINK1/Parkin-deficient states, accumulated ZNF746 further represses PGC-1α expression, creating a vicious cycle of mitochondrial dysfunction:
PINK1/PARKIN deficiency → ZNF746 accumulation → PGC-1α repression
↓ ↓
Mitochondrial dysfunction ←←←←←←←←←←←←←←←←←←←←←←←↓
This interaction positions ZNF746 as a molecular link between genetic forms of PD (PINK1, Parkin mutations) and sporadic disease pathogenesis.
ZNF746 exhibits a distinctive expression pattern in the central nervous system, with highest expression in:
| Brain Region | Expression Level | Functional Significance |
|-------------|-------------------|------------------------|
| Substantia nigra pars compacta | Very High | Dopaminergic neuron vulnerability in PD |
| Hippocampus | High | Memory impairment in neurodegenerative diseases |
| Cerebral cortex | Moderate-High | Executive dysfunction in PD/FTD |
| Cerebellum | Moderate | Motor coordination deficits |
| Striatum | High | Basal ganglia dysfunction in PD |
Within neurons, ZNF746 localizes primarily to the nucleus, where it functions as a transcriptional regulator. The protein is expressed in both dopaminergic and non-dopaminergic neurons, with particularly high expression in catecholaminergic neurons, which are selectively vulnerable in Parkinson's disease.
ZNF746 is expressed at moderate levels in peripheral tissues including:
ZNF746 was identified as a Parkinson's disease risk gene through GWAS meta-analysis, with single nucleotide polymorphisms (SNPs) in the ZNF746 locus associated with increased PD risk[@gwas]. The mechanism involves:
ZNF746 overexpression in PD models leads to:
Dopaminergic neurons in the substantia nigra exhibit:
Recent studies demonstrate that ZNF746 promotes alpha-synuclein aggregation and neurotoxicity[@pw3]:
ZNF746 modulates neuroinflammation through transcriptional regulation of cytokine and chemokine genes[@neuroinflammation]:
Emerging evidence links ZNF746 to ALS pathogenesis:
ZNF746 involvement in Alzheimer's disease includes:
Development of ZNF746 inhibitors represents a promising therapeutic approach[@therapy]:
| Compound Class | Mechanism | Development Stage | Challenges |
|---------------|-----------|-------------------|------------|
| DNA-binding blockers | Inhibit zinc finger DNA binding | Preclinical | Specificity |
| KRAB domain inhibitors | Block corepressor recruitment | Discovery | Bioavailability |
| HDAC inhibitors | Indirect modulation | Approved for other indications | Lack of specificity |
Alternatively, therapeutic strategies can bypass ZNF746 repression:
ZNF746 knockout mice exhibit:
ZNF746 overexpression models demonstrate:
The following diagram shows the key molecular relationships involving ZNF746 Gene discovered through SciDEX knowledge graph analysis: